Clinical Trials & Research
Many of today's most effective standard treatments are based on cancer research and the results of previous clinical studies. Ongoing research is essential in the fight against cancer, and it is one of the major objectives of the Edwards Comprehensive Cancer Center.
Clinical trials offer high quality cancer care and also allow current patients the opportunity to advance scientific knowledge and help future patients. The Edwards Comprehensive Cancer Center supports a very active clinical trials program and maintains a listing of the clinical trials that are currently available.
The Charles H. McKown, Jr., MD, Translational Genomic Research Institute (TGRI), which is housed on the third floor of the Edwards Comprehensive Cancer Center, allows scientists to work in close proximity to clinicians, fostering collaboration. This 10,500 square foot facility supports the medical school and clinical researchers by enabling them to rapidly translate genome-based laboratory research into clinical applications that will improve patient care. The McKown TGRI offers the appropriate environment for performing leading-edge cancer research and conducting clinical trials that are helping to shape the future of cancer research — and not just in Huntington.
ChemoID® is a proprietary second generation chemosensitivity assay that is commercially available in collaboration with Edwards Comprehensive Cancer Center and Cabell Huntington Hospital. It allows oncologists to determine how chemotherapy will impact an individual patient's cancer stem cells and tumor cells in the laboratory, before it is prescibed for the patient.
ChemoID® was developed by Marshall University biomedical sciences researcher Dr. Pier Paolo Claudio and Jagan Valluri, PhD, a professor of Cellular Biology and Integrative Medicine at Marshall University. Much of the research was conducted at the Translational Genomics Research Institute at the Edwards Comprehensive Cancer Center in Huntington, WV.
- Page last updated: Jan 5, 2016